• Signed informed consent form

• Documentation of tumor FRa expression by IHC at the Hospital of the University of Pennsylvania (≥ 10% of tumor cells). Subjects must have archived tumor tissue available.

• Disease-specific criteria:

• a. NSCLC Patients: i. Metastatic or recurrent lung adenocarcinoma with cytologically or pathologically confirmed malignant pleural effusion.

• ii. Failure of at least one prior line of standard of care therapy for advanced stage disease.

• Patients must have evidence of active disease as defined by RECIST 1.1 criteria

• Patients with asymptomatic CNS metastases that have been treated (and are off steroids for the treatment of CNS disease) are allowed. They must meet the following criteria

‣ No concurrent treatment for the CNS disease

⁃ No progression of CNS metastasis on MRI at screening

⁃ No evidence of leptomeningeal disease or cord compression

• Adequate organ function defined as:

‣ Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 30 cc/min; Patient must not be on dialysis

⁃ ALT/AST ≤ 3x upper limit of normal range

⁃ Serum total bilirubin ≤ 1.5 mg/dl, unless the subject has Gilbert's syndrome (if so, serum total bilirubin must be ≤ 3.0 mg/dl)

⁃ Must have a minimum level of pulmonary reserve defined as \< Grade 1 dyspnea and pulse oxygen \> 92% on room air

⁃ Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO or MUGA

• Male or female age ≥ 18 years

• Eastern Cooperative Oncology Group (ECOG) Performance Status that is either 0 or 1

• Subjects must be a possible clinical candidate for standard of care treatment with a commercial checkpoint inhibitor, as per physician-investigator assessment.